This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Biologics, Inc.
Biologics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in the early 2000s, the company has achieved significant milestones, including the development of innovative therapies that address complex medical conditions. Specialising in biologic drugs, Biologics, Inc. offers a range of products that are distinguished by their advanced manufacturing processes and commitment to quality. Their core services include drug development, distribution, and patient support, ensuring that healthcare providers and patients receive the best possible outcomes. With a strong market position, Biologics, Inc. has garnered recognition for its contributions to the field, making it a trusted name among healthcare professionals and patients alike.
DitchCarbon Score
How does Biologics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biologics, Inc.'s score of 47 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biologics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of McKesson Corporation, which may influence its climate commitments and reporting practices. As part of its corporate family, Biologics, Inc. inherits climate initiatives and targets from McKesson Corporation. However, there are no documented reduction targets or significant climate pledges available for Biologics, Inc. at this time. The lack of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of developing its climate strategy. In the broader context, McKesson Corporation, as the parent company, may have established sustainability goals and initiatives that could impact Biologics, Inc.'s future commitments. However, without explicit data or targets from Biologics, Inc., it is challenging to provide a detailed overview of its carbon emissions and climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 92,194,000 | 00,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 188,912,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 28,733,000 | 00,000,000 | 00,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biologics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
